Rep. Mike Kelly Sells Shares of Bristol Myers Squibb Company (NYSE:BMY)

Representative Mike Kelly (Republican-Pennsylvania) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on June 11th, the Representative disclosed that they had sold between $15,001 and $50,000 in Bristol Myers Squibb stock on May 7th. The trade occurred in the Representative’s “VICTORIA KELLY TRUST ICA” account.

Representative Mike Kelly also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Comcast (NASDAQ:CMCSA) on 5/7/2026.

Bristol Myers Squibb Stock Performance

BMY opened at $55.61 on Wednesday. The business has a fifty day simple moving average of $57.19 and a 200 day simple moving average of $57.22. The company has a market capitalization of $113.56 billion, a PE ratio of 15.62, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter last year, the business earned $1.80 EPS. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Investors of record on Thursday, July 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.5%. The ex-dividend date of this dividend is Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 70.79%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. Wall Street Zen lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. UBS Group reissued a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Cantor Fitzgerald boosted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, April 8th. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $61.31.

Institutional Investors Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Swiss RE Ltd. bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $25,000. Darwin Wealth Management LLC acquired a new position in Bristol Myers Squibb during the second quarter worth about $25,000. Physician Wealth Advisors Inc. raised its stake in Bristol Myers Squibb by 73.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares in the last quarter. Bayban bought a new position in shares of Bristol Myers Squibb in the fourth quarter worth about $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at approximately $32,000. 76.41% of the stock is currently owned by institutional investors.

Insider Activity

In related news, EVP David V. Elkins sold 30,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.05% of the company’s stock.

About Representative Kelly

Mike Kelly (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 16th Congressional District. He assumed office on January 3, 2019. His current term ends on January 3, 2027.

Kelly (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 16th Congressional District. He declared candidacy for the 2026 election.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.